« Return to News | CROs/Service Providers

Pfizer Expands Relationship with Indian CRO TCG Lifesciences

Wednesday, January 6, 2010 09:21 AM

Pfizer is expanding an agreement with Indian contract research organization (CRO) TCG Lifesciences to include integrated research services.

Bangalore-based TCG Lifesciences has been a preferred provider of discovery chemistry services for Pfizer since 2005. Under the new agreement, the CRO will provide services in other areas, including the synthesis of monomer and templates, medicinal chemistry and parallel medicinal chemistry. Neither company released the financial terms of the deal, but, according to published reports, it will extend for more than two years with possible milestone payments paid to TCG along the way.

"We are excited at the prospect of supporting Pfizer across the drug discovery and development value chain in an integrated manner,” said TCG’s managing director Swapan Bhattacharya. “This development is of great importance for us as it signifies our competences in providing innovation based integrated research services from early stage discovery to kilo scale production of first in man material".

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.